SecBot SecBot
PRESS-RELEASE ·Filed May 14, 2026

BIIB

Biogen Inc.
MIXED
Impact 6/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ◆ Mixed

The mixed CELIA results may cause near-term volatility. Watch for regulatory feedback and details on the registrational trial design. Tau-directed therapy is a new mechanism; initial market reaction could be positive on cognitive signals, but primary endpoint miss tempers enthusiasm.

DirectionMixed
Confidencemedium
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$191.26
T+0 close · May 14, 2026 · via day close
Latest settled
+8.15%
T+60 · $206.85
Vs SPY
+4.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $191.26entry
  2. T+1 · 6mo ago +0.55%α +1.78% · $192.32
  3. T+5 · 6mo ago −0.93%α −0.22% · $189.47
  4. T+20 · 5mo ago +4.60%α +5.46% · $200.05
  5. T+60 · 3mo ago +8.15%α +4.83% · $206.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Biogen reported mixed Phase 2 CELIA results for diranersen in early Alzheimer's disease. The study missed its primary endpoint (dose response on CDR-SB) but showed slowing of cognitive decline in pre-specified analyses and robust tau reduction across doses. Biogen plans to advance to registrational development, creating a mixed outlook for the stock.

Key Facts

  • Phase 2 CELIA study (n=416) of diranersen (BIIB080) in early Alzheimer's disease did not meet its primary endpoint of dose response on CDR-SB at Week 76.
  • Pre-specified analyses showed slowing of clinical decline, particularly at the lowest dose (60 mg every 24 weeks).
  • Robust reductions in CSF tau and tau PET across all doses, consistent with Phase 1b data.
  • Safety profile generally consistent with prior studies; higher serious adverse events at highest dose.
  • Biogen plans to engage regulators and initiate registrational development.
  • FDA granted Fast Track designation in 2025.

Financial Impact

No financial data in release. Potential market for tau-targeting Alzheimer's therapy is large, but clinical and regulatory path remains uncertain.

Risk Factors

  • Primary endpoint miss may raise regulatory hurdles and require larger confirmatory trial.
  • Higher serious adverse events at highest dose could limit dosing or risk-benefit profile.
  • Competition from amyloid-targeting therapies and other tau-directed programs.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
56% bullish (43 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3294711

Track record

34 reports on BIIB

Performance horizon

10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
  4. Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  5. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  6. Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
  7. Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
  8. Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
  9. Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
  10. Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (11h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026